| Name | Title | Contact Details |
|---|
Turner Surety and Insurance Brokerage, Inc. (TSIB) is a full-service brokerage that specializes in controlled insurance programs and traditional property and casualty placements. The company focuses on construction risk management, serving owners, developers, and contractors. TSIB has extensive experience in managing construction risks, particularly through Controlled Insurance Programs (CIPs) and Owner-Controlled Insurance Programs (OCIPs), ensuring effective risk management and safety controls. TSIB has worked on over 450 healthcare projects, totaling more than $20 billion in construction volume. They offer customized insurance programs and reinsurance solutions, supporting the Managing General Agent (MGA) community. Their services also include consulting for professional services, surety programs, and various health-related benefits. TSIBs expertise in Wrap-Up programs helps manage construction projects comprehensively, from orientation to financial auditing.
NCD is dedicated to improving lives by driving better health, providing an exceptional experience, and Spreading the Smile. As the costs of dental and vision insurance continue to increase across the country, our mission is to provide comprehensive dental and vision care thats accessible, quick to obtain, and simple to use. Whether youre uninsured or under-insured, NCD has a plan that fits your dental and vision needs.
A private Class C Bermuda-based reinsurance company offering customized solutions to address our clients unique needs.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.